Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864462 | 1.00 | USP2 (0.42) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL5106731 | 0.95 | TACR2 (0.39) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL4631280 | 0.88 | TACR2 (0.49) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL380713 | 0.88 | USP2 (0.41) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL380714 | 0.88 | USP2 (0.41) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL3977770 | 0.87 | KMT2A (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL3985942 | 0.87 | KMT2A (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL5106738 | 0.86 | TACR2 (0.38) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL4870849 | 0.86 | TACR2 (0.38) | USP2CYP3A4CYP1A2TSHRCYP2D6 | |
| SCHEMBL4631196 | 0.86 | TACR2 (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | USP2 4432/4885CYP3A4 366/4885CYP1A2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.